{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:08:47Z","timestamp":1793286527930,"version":"4.5.0"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,18]],"date-time":"2020-01-18T00:00:00Z","timestamp":1579305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.jare.2020.01.008","type":"journal-article","created":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T20:38:38Z","timestamp":1579639118000},"page":"163-205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":113,"special_numbering":"C","title":["An overview on medicinal perspective of thiazolidine-2,4-dione: A remarkable scaffold in the treatment of type 2 diabetes"],"prefix":"10.1016","volume":"23","author":[{"given":"Garima","family":"Bansal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4249-7962","authenticated-orcid":false,"given":"Punniyakoti Veeraveedu","family":"Thanikachalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul K.","family":"Maurya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7844-9172","authenticated-orcid":false,"given":"Pooja","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasan","family":"Ramamurthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jare.2020.01.008_b0005","unstructured":"IDF diabetes atlas - Home 2017. http:\/\/www.diabetesatlas.org\/ (accessed March 8, 2019)."},{"key":"10.1016\/j.jare.2020.01.008_b0010","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1021\/jm030626a","article-title":"Novel \u201csecond-generation\u201d approaches for the control of Type 2 diabetes","volume":"47","author":"Rotella","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0015","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13065-017-0357-2","article-title":"Biological potential of thiazolidinedione derivatives of synthetic origin","volume":"11","author":"Sucheta","year":"2017","journal-title":"Chem Cent J"},{"key":"10.1016\/j.jare.2020.01.008_b0020","first-page":"225","article-title":"Studies on the synthesis of novel 2, 4-thiazolidinedione derivatives with antidiabetic activity","volume":"5","author":"Pattan","year":"2009","journal-title":"Iran J Pharm Sci"},{"key":"10.1016\/j.jare.2020.01.008_b0025","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2020.01.008_b0030","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.2337\/diab.45.12.1661","article-title":"Thiazolidinediones in the treatment of insulin resistance and type II diabetes","volume":"45","author":"Saltiel","year":"1996","journal-title":"Diabetes"},{"key":"10.1016\/j.jare.2020.01.008_b0035","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ejmech.2017.02.031","article-title":"Therapeutic journey of 2,4-thiazolidinediones as a versatile scaffold: An insight into structure activity relationship","volume":"129","author":"Naim","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0040","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bioorg.2017.10.014","article-title":"Synthetic and medicinal perspective of thiazolidinones: A review","volume":"75","author":"Kaur Manjal","year":"2017","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0045","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.2174\/092986709788186200","article-title":"Rhodanine as a privileged scaffold in drug discovery","volume":"16","author":"Tomasic","year":"2009","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0050","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11094-016-1416-z","article-title":"Synthesis and evaluation of the hypoglycemic and hypolipidemic activity of novel arylidene thiazolidinedione analogson a type 2 diabetes model","volume":"50","author":"Ahmadi","year":"2016","journal-title":"Pharm Chem J"},{"key":"10.1016\/j.jare.2020.01.008_b0055","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1464-5491.1999.00023.x","article-title":"Thiazolidinediones: a new class of antidiabetic drugs","volume":"16","author":"Day","year":"1999","journal-title":"Diabet Med"},{"key":"10.1016\/j.jare.2020.01.008_b0060","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.bioorg.2018.02.009","article-title":"Thiazolidinediones as antidiabetic agents: A critical review","volume":"77","author":"Nanjan","year":"2018","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0065","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cmet.2014.08.005","article-title":"Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes","volume":"20","author":"Soccio","year":"2014","journal-title":"Cell Metab"},{"key":"10.1016\/j.jare.2020.01.008_b0070","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1463-1326.2009.01080.x","article-title":"Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: Results of the GALIANT trial - a primary care, type 2 diabetes study","volume":"11","author":"Blonde","year":"2009","journal-title":"Diabetes, Obes Metab"},{"key":"10.1016\/j.jare.2020.01.008_b0075","unstructured":"TriMaster: study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as third line therapy in patients with type 2 diabetes n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02653209 (accessed March 8, 2019)."},{"key":"10.1016\/j.jare.2020.01.008_b0080","unstructured":"Effects of fats on blood glucose in people with and without type 2 diabetes mellitus n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00308373 (accessed March 8, 2019)."},{"key":"10.1016\/j.jare.2020.01.008_b0085","unstructured":"Fracture risk with thiazolidinediones n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01055223 (accessed March 8, 2019)."},{"key":"10.1016\/j.jare.2020.01.008_b0090","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(10)60590-9","article-title":"Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial","volume":"376","author":"Bergenstal","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jare.2020.01.008_b0095","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1007\/s00125-006-0244-1","article-title":"Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation","volume":"49","author":"Pers\u00e9gol","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.jare.2020.01.008_b0100","unstructured":"Comparison of lobeglitazone with pioglitazone as initial triple therapy for diabetes management n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02315287 (accessed March 8, 2019)."},{"key":"10.1016\/j.jare.2020.01.008_b0105","unstructured":"Effect of different interventions on glycemic control and \u03b2-cell function in newly diagnosed type 2 diabetic patients n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01147627 (accessed March 8, 2019)."},{"key":"10.1016\/j.jare.2020.01.008_b0110","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S2213-8587(17)30317-0","article-title":"Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial","volume":"5","author":"Vaccaro","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jare.2020.01.008_b0115","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1001\/archinte.167.12.1284","article-title":"Low-dose rosiglitazone in patients with insulin-requiring type 2 diabetes","volume":"167","author":"Hollander","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jare.2020.01.008_b0120","unstructured":"Comparison of the effects of thiazolidinediones(TZD), sodium- glucose cotransporter 2 inhibitors(SGLT2i) alone and TZD \/ SGLT2i combination therapy on non-alcoholic fatty liver disease in type 2 diabetic patients with fatty liver n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03646292 (accessed March 8, 2019)."},{"key":"10.1016\/j.jare.2020.01.008_b0125","unstructured":"Comparison of pioglitazone versus glimepiride in type 2 diabetes inadequately controlled with metformin plus alogliptin n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02426294 (accessed March 8, 2019)."},{"key":"10.1016\/j.jare.2020.01.008_b0130","unstructured":"A trial of TT223 in patients with type 2 diabetes who are taking metformin and\/or thiazolidinedione n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00743002 (accessed March 8, 2019)."},{"key":"10.1016\/j.jare.2020.01.008_b0135","unstructured":"AVANDIA with glyburide in African American and hispanic patients with type 2 diabetes not controlled by glyburide alone n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00333723 (accessed March 9, 2019)."},{"key":"10.1016\/j.jare.2020.01.008_b0140","unstructured":"A study to evaluate the effectiveness and safety initiation and titration of insulin glargine (U300) in insulin-na\u00efve patients with type 2 diabetes mellitus (T2DM) controlled on oral antidiabetic drug treatment in Turkey n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02954692 (accessed March 8, 2019)."},{"key":"10.1016\/j.jare.2020.01.008_b0145","doi-asserted-by":"crossref","first-page":"i581","DOI":"10.1136\/bmj.i581","article-title":"Incretin based drugs and the risk of pancreatic cancer: International multicentre cohort study","volume":"352","author":"Azoulay","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jare.2020.01.008_b0150","unstructured":"Evaluate the glycemic control of CKD-501 in type 2 diabetes mellitus n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01030679 (accessed March 8, 2019)."},{"key":"10.1016\/j.jare.2020.01.008_b0155","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/jdi.12157","article-title":"Pioglitazone and metformin are equally effective in reduction of chemerin in patients with type 2 diabetes","volume":"5","author":"Esteghamati","year":"2014","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jare.2020.01.008_b0160","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1007\/s00125-013-2976-z","article-title":"Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3\u2013TACE dyad in type 2 diabetes mellitus: A randomised, double-blind, placebo-controlled, mechanistic study","volume":"56","author":"Tripathy","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.jare.2020.01.008_b0165","unstructured":"Rosiglitazone-metformin combination versus metformin-sulfonylurea combination on beta-cell function in type 2 diabetes n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00367055 (accessed March 8, 2019)."},{"key":"10.1016\/j.jare.2020.01.008_b0170","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1001\/jamainternmed.2016.1522","article-title":"Association between incretin-based drugs and the risk of acute pancreatitis","volume":"176","author":"Azoulay","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jare.2020.01.008_b0175","unstructured":"A study of LY2189265 in Japanese participants with type 2 diabetes mellitus n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01468181 (accessed March 8, 2019)."},{"key":"10.1016\/j.jare.2020.01.008_b0180","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.dsx.2014.09.009","article-title":"Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial","volume":"9","author":"Esteghamati","year":"2015","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.jare.2020.01.008_b0185","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/jdi.12092","article-title":"Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus","volume":"4","author":"Kadowaki","year":"2013","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jare.2020.01.008_b0190","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2337\/dc16-1738","article-title":"Combination therapy with exenatide plus pioglitazone versus basal\/bolus insulin in patients with poorly controlled type 2 diabetes on sulfonylurea plus metformin: The qatar study","volume":"40","author":"Abdul-Ghani","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jare.2020.01.008_b0195","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.metabol.2009.08.005","article-title":"Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus","volume":"59","author":"Kadoglou","year":"2010","journal-title":"Metabolism"},{"key":"10.1016\/j.jare.2020.01.008_b0200","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/03007995.2016.1261817","article-title":"Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs","volume":"33","author":"Okuda","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jare.2020.01.008_b0205","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1185\/030079903125002306","article-title":"Is weight loss possible in patients treated with thiazolidinediones? Experience with a low-calorie diet","volume":"19","author":"Asnani","year":"2003","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jare.2020.01.008_b0210","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.carrev.2008.06.004","article-title":"Comparison of bare metal stent with pioglitazone versus sirolimus-eluting stent for percutaneous coronary intervention in patients with type 2 diabetes mellitus","volume":"10","author":"Nishio","year":"2009","journal-title":"Cardiovasc Revascularization Med"},{"key":"10.1016\/j.jare.2020.01.008_b0215","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3346\/jkms.2017.32.1.60","article-title":"Lobeglitazone, a novel thiazolidinedione, improves non-alcoholic fatty liver disease in type 2 diabetes: Its efficacy and predictive factors related to responsiveness","volume":"32","author":"Lee","year":"2017","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.jare.2020.01.008_b0220","unstructured":"Vascular effects of rosiglitazone versus glyburide in type 2 diabetic patients n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00123643 (accessed March 8, 2019)."},{"key":"10.1016\/j.jare.2020.01.008_b0225","unstructured":"Fatty liver study in patients with type II diabetes n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02365233 (accessed March 8, 2019)."},{"key":"10.1016\/j.jare.2020.01.008_b0230","unstructured":"Placebo controlled dose-response study of rivoglitazone in type 2 diabetes n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00575471 (accessed March 8, 2019)."},{"key":"10.1016\/j.jare.2020.01.008_b0235","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1056\/NEJMoa1506115","article-title":"A multicenter observational study of incretin-based drugs and heart failure","volume":"374","author":"Filion","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2020.01.008_b0240","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00125-011-2357-4","article-title":"Design, history and results of the thiazolidinedione intervention with vitamin D evaluation (TIDE) randomised controlled trial","volume":"55","author":"Punthakee","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.jare.2020.01.008_b0245","unstructured":"Prevention of instent renarrowing with aggressive glucose lowering with pioglitazone in diabetic patients n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00819325 (accessed March 8, 2019)."},{"key":"10.1016\/j.jare.2020.01.008_b0250","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jare.2020.01.008_b0255","unstructured":"Efficacy in controlling glycaemia with Victoza\u00ae (liraglutide) as add-on to metformin vs. OADs as add-on to metformin after up to 104 weeks of treatment in subjects with type 2 diabetes n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02730377 (accessed March 8, 2019)."},{"key":"10.1016\/j.jare.2020.01.008_b0260","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ahj.2008.05.015","article-title":"Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial","volume":"156","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.jare.2020.01.008_b0265","unstructured":"Placebo and active comparator controlled dose response study of rivoglitazone in type 2 diabetes n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00575874 (accessed March 8, 2019)."},{"key":"10.1016\/j.jare.2020.01.008_b0270","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.metabol.2009.02.020","article-title":"Impact of rosiglitazone and glyburide on nitrosative stress and myocardial blood flow regulation in type 2 diabetes mellitus","volume":"58","author":"Pop-Busui","year":"2009","journal-title":"Metabolism"},{"key":"10.1016\/j.jare.2020.01.008_b0275","unstructured":"The practical evidence of antidiabetic combination therapy in Korea n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02231021 (accessed March 8, 2019)."},{"key":"10.1016\/j.jare.2020.01.008_b0280","doi-asserted-by":"crossref","first-page":"e92843","DOI":"10.1371\/journal.pone.0092843","article-title":"Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: A multicenter, randomized, double-blind, parallel-group, placebo controlled trial","volume":"9","author":"Kim","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jare.2020.01.008_b0285","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2337\/dc11-1107","article-title":"Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): A 26-week double-blind study","volume":"35","author":"Russell-Jones","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jare.2020.01.008_b0290","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/dc11-1693","article-title":"Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jare.2020.01.008_b0295","unstructured":"Pharmacogenomics of thiazolidinediones n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01135394 (accessed March 8, 2019)."},{"key":"10.1016\/j.jare.2020.01.008_b0300","unstructured":"Predictive markers of glitazone efficacy in diabetic patients - pilot study n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00481429 (accessed March 8, 2019)."},{"key":"10.1016\/j.jare.2020.01.008_b0305","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1210\/jc.2009-0550","article-title":"CV181-013 Investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone","volume":"94","author":"Hollander","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jare.2020.01.008_b0310","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.phrs.2004.07.012","article-title":"An overview on biological mechanisms of PPARs","volume":"51","author":"Kota","year":"2005","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jare.2020.01.008_b0315","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/MJT.0b013e3181c08081","article-title":"PPAR-\u03b3 agonists and their role in type 2 diabetes mellitus management","volume":"17","author":"Berm\u00fadez","year":"2010","journal-title":"Am J Ther"},{"key":"10.1016\/j.jare.2020.01.008_b0320","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.2337\/diabetes.53.2007.S43","article-title":"The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity","volume":"53","author":"Ferr\u00e9","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.jare.2020.01.008_b0325","first-page":"864","article-title":"The role of PPAR agonists in diabetes mellitus","volume":"8","author":"Muralidaran","year":"2016","journal-title":"J Pharm Sci Res"},{"key":"10.1016\/j.jare.2020.01.008_b0330","doi-asserted-by":"crossref","first-page":"67","DOI":"10.18773\/austprescr.2004.059","article-title":"Thiazolidinediones - mechanisms of action","volume":"27","author":"Greenfield","year":"2004","journal-title":"Aust Prescr"},{"key":"10.1016\/j.jare.2020.01.008_b0335","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1002\/dmrr.249","article-title":"The mode of action of thiazolidinediones","volume":"18","author":"Hauner","year":"2002","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.jare.2020.01.008_b0340","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-J\u00e4rvinen","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2020.01.008_b0345","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.tem.2012.03.001","article-title":"Thiazolidinediones and PPAR\u03b3 agonists: Time for a reassessment","volume":"23","author":"Cariou","year":"2012","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.jare.2020.01.008_b0350","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1248\/cpb.39.1440","article-title":"Studies on antidiabetic agents. X. Synthesis and biological activities of pioglitazone and related compounds","volume":"39","author":"Momose","year":"1991","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.jare.2020.01.008_b0355","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1021\/jm00092a012","article-title":"Meguro K. Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents","volume":"35","author":"Sohda","year":"1992","journal-title":"J Med Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0360","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.1021\/jm9605694","article-title":"Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent pioglitazone","volume":"39","author":"Tanis","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0365","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1021\/jm970444e","article-title":"Novel euglycemic and hypolipidemic agents","volume":"41","author":"Lohray","year":"1998","journal-title":"J Med Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0370","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1021\/jm980622j","article-title":"Novel euglycemic and hypolipidemic agents. 4. Pyridyl- and quinolinyl- containing thiazolidinediones","volume":"42","author":"Lohray","year":"1999","journal-title":"J Med Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0375","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1021\/jm990522t","article-title":"Molecular design, synthesis, and hypoglycemic activity of a series of thiazolidine-2, 4-diones","volume":"43","author":"Oguchi","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0380","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0223-5234(01)01257-0","article-title":"Novel phthalazinone and benzoxazinone containing thiazolidinediones as antidiabetic and hypolipidemic agents","volume":"36","author":"Madhavan","year":"2001","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0385","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1016\/S0968-0896(02)00107-4","article-title":"Synthesis and biological activity of novel pyrimidinone containing thiazolidinedione derivatives","volume":"10","author":"Madhavan","year":"2002","journal-title":"Bioorganic Med Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0390","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1021\/bc025606m","article-title":"Vanadyl-thiazolidinedione combination agents for diabetes therapy","volume":"14","author":"Storr","year":"2003","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0395","doi-asserted-by":"crossref","first-page":"6718","DOI":"10.1074\/jbc.274.10.6718","article-title":"Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPAR delta ligands produce distinct biological effects","volume":"274","author":"Berger","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0400","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0960-894X(03)00257-9","article-title":"5-aryl thiazolidine-2, 4-diones as selective PPAR agonists","volume":"13","author":"Koyama","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jare.2020.01.008_b0405","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ejmech.2004.03.001","article-title":"Synthesis and biological activity of novel substituted pyridines and purines containing 2,4-thiazolidinedione","volume":"39","author":"Kim","year":"2004","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0410","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.bmcl.2004.12.041","article-title":"Synthesis and pharmacological evaluation of substituted 5-[4-[2-(6, 7-dimethyl-1, 2, 3, 4-tetrahydro-2-oxo-4-quinoxalinyl) ethoxy] phenyl] methylene] thiazolidine-2, 4-dione derivatives as potent euglycemic and hypolipidemic agents","volume":"15","author":"Gupta","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jare.2020.01.008_b0415","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ejmech.2005.03.019","article-title":"Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione","volume":"40","author":"Lee","year":"2005","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0420","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/BF02980237","article-title":"Synthesis and biological activity of 5- 4- [2- (Methyl- p -substi- tuted phenylamino) ethoxy ] benzyl thiazolidine-2, 4-diones","volume":"30","author":"Gim","year":"2007","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.jare.2020.01.008_b0425","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ejmech.2012.04.015","article-title":"Synthesis, hypoglycemic and hypolipidemic activities of novel thiazolidinedione derivatives containing thiazole\/triazole\/oxadiazole ring","volume":"53","author":"Mohammed Iqbal","year":"2012","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0430","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1007\/s00044-011-9792-0","article-title":"Novel glitazones : glucose uptake and cytotoxic activities, and structure \u2013 activity relationships","volume":"21","author":"Kumar","year":"2012","journal-title":"Med Chem Res"},{"issue":"5","key":"10.1016\/j.jare.2020.01.008_b0435","doi-asserted-by":"crossref","first-page":"834","DOI":"10.2174\/157340612802084388","article-title":"Synthesis, Characterization, Biological Evaluation and Docking of Coumarin Coupled Thiazolidinedione Derivatives and its Bioisosteres as PPAR\u03b3 Agonists","volume":"8","author":"Shukla","year":"2012","journal-title":"med chem"},{"key":"10.1016\/j.jare.2020.01.008_b0440","first-page":"189","article-title":"Design synthesis and antidiabetic evaluation of new cyanoquinoloxy benzylidenyl 2,4-thiazolidinediones","volume":"6","author":"Deshmukha","year":"2016","journal-title":"Chem Biol Interface"},{"key":"10.1016\/j.jare.2020.01.008_b0445","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bioorg.2017.11.010","article-title":"Design, synthesis and molecular docking of thiazolidinedione based benzene sulphonamide derivatives containing pyrazole core as potential anti-diabetic agents","volume":"76","author":"Naim","year":"2018","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0450","first-page":"E175","article-title":"Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues","volume":"291","author":"LeBrasseur","year":"2006","journal-title":"Am J Physiol Metab"},{"key":"10.1016\/j.jare.2020.01.008_b0455","doi-asserted-by":"crossref","first-page":"1700223","DOI":"10.1002\/ardp.201700223","article-title":"Synthesis, docking, in vitro and in vivo antidiabetic activity of pyrazole-based 2,4-thiazolidinedione derivatives as PPAR-\u03b3 modulators","volume":"351","author":"Naim","year":"2018","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1016\/j.jare.2020.01.008_b0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103271","article-title":"Synthesis and biological evaluation of thiazolidine-2,4-dione-pyrazole conjugates as antidiabetic, anti-inflammatory and antioxidant agents","volume":"92","author":"Bansal","year":"2019","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0465","doi-asserted-by":"crossref","first-page":"S196","DOI":"10.1016\/j.jscs.2012.10.010","article-title":"Design and synthesis of novel thiazolidine-2,4-diones as hypoglycemic agents","volume":"20","author":"Datar","year":"2016","journal-title":"J Saudi Chem Soc"},{"key":"10.1016\/j.jare.2020.01.008_b0470","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0014-827X(02)01241-7","article-title":"Synthesis and hypoglycemic activity of some substituted flavonyl thiazolidinedione derivatives - Fifth communication: Flavonyl benzyl substituted 2,4-thiazolidinediones","volume":"58","author":"Tun\u00e7bilek","year":"2003","journal-title":"Farmaco"},{"key":"10.1016\/j.jare.2020.01.008_b0475","doi-asserted-by":"crossref","first-page":"6747","DOI":"10.1016\/j.bmc.2008.05.059","article-title":"Synthesis and biological activity of some new flavonyl-2,4-thiazolidinediones","volume":"16","author":"Bozda\u01e7-D\u00fcndar","year":"2008","journal-title":"Bioorganic Med Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0480","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1021\/jm9706168","article-title":"Novel 5-(3-aryl-2-propynyl)-5-(arylsulfonyl)thiazolidine-2,4-diones as antihyperglycemic agents","volume":"41","author":"Wrobel","year":"1998","journal-title":"J Med Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0485","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.bmcl.2011.10.110","article-title":"Synthesis and antihyperglycemic evaluation of new 2,4-thiazolidinediones having biodynamic aryl sulfonylurea moieties","volume":"22","author":"Jawale","year":"2012","journal-title":"Bioorganic Med Chem Lett"},{"key":"10.1016\/j.jare.2020.01.008_b0490","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1016\/S0960-894X(98)00485-5","article-title":"Synthesis and biological activity of novel thiazolidinediones","volume":"8","author":"Prabhakar","year":"1998","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jare.2020.01.008_b0495","first-page":"13","article-title":"Synthesis and biological evaluation of some 5-substituted phenothiazine based thiazoli- dine-2, 4-dione derivatives","volume":"4","author":"Saini","year":"2018","journal-title":"MIT Int J Pharm Sci"},{"key":"10.1016\/j.jare.2020.01.008_b0500","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1021\/jm0510880","article-title":"Design and synthesis of the first generation of dithiolane thiazolidinedione- and phenylacetic acid-based PPARy agonists","volume":"49","author":"Chittiboyina","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0505","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/j.bmcl.2010.01.125","article-title":"Novel glitazones : Design, synthesis, glucose uptake and structure \u2013 activity relationships","volume":"20","author":"Kumar","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jare.2020.01.008_b0510","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.ejmech.2010.12.019","article-title":"Synthesis, glucose uptake activity and structure e activity relationships of some novel glitazones incorporated with glycine, aromatic and alicyclic amine moieties via two carbon acyl linker","volume":"46","author":"Kumar","year":"2011","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0515","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s00044-010-9359-5","article-title":"Synthesis and evaluation of the hypoglycemic and hypolipidemic activity of novel 5-benzylidene-2,4-thiazolidinedione analogs in a type-2 diabetes model","volume":"20","author":"Mehendale-Munj","year":"2011","journal-title":"Med Chem Res"},{"key":"10.1016\/j.jare.2020.01.008_b0520","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1007\/s00044-016-1675-y","article-title":"Design, synthesis and evaluation of novel thiazolidinedione derivatives as anti-hyperglycemic and anti-hyperlipidemic agents","volume":"25","author":"Shrivastava","year":"2016","journal-title":"Med Chem Res"},{"key":"10.1016\/j.jare.2020.01.008_b0525","first-page":"390","article-title":"Design synthesis and evaluation of novel thiazolidinedione derivatives as antidiabetic agents","volume":"6","author":"Dadasaheb","year":"2017","journal-title":"Pharma Innov J"},{"key":"10.1016\/j.jare.2020.01.008_b0530","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bioorg.2017.05.007","article-title":"Synthesis, molecular docking and anti-diabetic evaluation of 2,4-thiazolidinedione based amide derivatives","volume":"73","author":"Naim","year":"2017","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0535","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/cbdd.12140","article-title":"Synthesis, hypoglycaemic, hypolipidemic and ppar-y agonist activities of 5-(2-alkyl\/aryl-6-arylimidazo[2,1-b][1,3,4]thiadiazol-5-yl)methylene-1,3-thiazolidinediones","volume":"82","author":"Khazi","year":"2013","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.jare.2020.01.008_b0540","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1016\/j.ejmech.2009.03.035","article-title":"Synthesis and in vivo antidiabetic activity of novel dispiropyrrolidines through [3 + 2] cycloaddition reactions with thiazolidinedione and rhodanine derivatives","volume":"44","author":"Murugan","year":"2009","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0545","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1016\/S0968-0896(03)00393-6","article-title":"Synthesis and structure-activity relationship studies of cinnamic acid-based novel thiazolidinedione antihyperglycemic agents","volume":"11","author":"Neogi","year":"2003","journal-title":"Bioorganic Med Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0550","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/ardp.201400280","article-title":"Design, synthesis, and biological evaluation of thiazolidine-2,4-dione conjugates as PPAR-\u03b3 agonists","volume":"348","author":"Nazreen","year":"2015","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1016\/j.jare.2020.01.008_b0555","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.biopha.2017.01.160","article-title":"Novel thiazolidinedione-5-acetic-acid-peptide hybrid derivatives as potent antidiabetic and cardioprotective agents","volume":"88","author":"Maji","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jare.2020.01.008_b0560","first-page":"5068","article-title":"Synthesis of some novel 2, 4-thiazolidinedione derivatives and their biological screening as antidiabetic agents","volume":"21","author":"Jiwane","year":"2009","journal-title":"Asian J Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0565","doi-asserted-by":"crossref","first-page":"6442","DOI":"10.1016\/j.bmcl.2012.08.052","article-title":"Synthesis, characterization and biological evaluation of some novel 2,4-thiazolidinediones as potential cytotoxic, antimicrobial and antihyperglycemic agents","volume":"22","author":"Avupati","year":"2012","journal-title":"Bioorganic Med Chem Lett"},{"key":"10.1016\/j.jare.2020.01.008_b0570","first-page":"216","article-title":"Evaluation of thiazolidinedione derivatives for acute toxicity and potential antidiabetic activity","volume":"7","author":"Patil","year":"2015","journal-title":"Der Pharma Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0575","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4172\/2161-0444.1000409","article-title":"Microwave Assisted Synthesis and Antidiabetic Activity of Novel 5-[4-(Substituted) Benzylidine]Thiazolidine-2,4-Dione","volume":"6","author":"Patel","year":"2016","journal-title":"Med Chem (Los Angeles)"},{"key":"10.1016\/j.jare.2020.01.008_b0580","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.yrtph.2017.02.008","article-title":"In silico design, chemical synthesis and toxicological evaluation of 1,3-thiazolidine-2,4-dione derivatives as PPAR\u03b3 agonists","volume":"86","author":"Alem\u00e1n-Gonz\u00e1lez-Duhart","year":"2017","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.jare.2020.01.008_b0585","unstructured":"S. R, S. C. Novel substituted thiazolidinedione derivatives as anti-diabetic agents. Eur J Pharm Med Res 2017; 4: 643\u201352."},{"key":"10.1016\/j.jare.2020.01.008_b0590","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1021\/jm980549x","article-title":"Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones","volume":"42","author":"Reddy","year":"1999","journal-title":"J Med Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0595","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/BF02975111","article-title":"Synthesis and biological activity of benzoxazole containing thiazolidinedione derivatives","volume":"27","author":"Jeon","year":"2004","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.jare.2020.01.008_b0600","first-page":"2404","article-title":"Synthesis and antidiabetic activity of 2-amino[5(4-sulphonylbenzylidine)-2,4-thiazolidinedione]-7-chloro-6- fluorobenzothiazole","volume":"44","author":"Pattan","year":"2005","journal-title":"Indian J Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0605","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/BF02968589","article-title":"Synthesis and biological activity of [[(heterocycloamino) alkoxy ] benzyl ] -2, 4-thiazolidinediones as PPARy agonists","volume":"29","author":"Jeon","year":"2006","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.jare.2020.01.008_b0610","first-page":"26","article-title":"Benzisoxazole containing thiazolidinediones as peroxisome proliferator activated receptor- \u03b3 agonists : Design, molecular docking, synthesis & anti - diabetic studies","volume":"3","author":"Purohit","year":"2014","journal-title":"Sch Acad J Pharm"},{"key":"10.1016\/j.jare.2020.01.008_b0615","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3109\/14756366.2012.723207","article-title":"Synthesis and antidiabetic activity of 2,4-thiazolidindione, imidazolidinedione and 2-thioxo-imidazolidine-4-one derivatives bearing 6-methyl chromonyl pharmacophore","volume":"28","author":"Unlusoy","year":"2013","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.jare.2020.01.008_b0620","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1016\/j.bmcl.2014.05.034","article-title":"Thiazolidine-2,4-diones derivatives as PPAR-\u03b3 agonists: Synthesis, molecular docking, in vitro and in vivo antidiabetic activity with hepatotoxicity risk evaluation and effect on PPAR-\u03b3 gene expression","volume":"24","author":"Nazreen","year":"2014","journal-title":"Bioorganic Med Chem Lett"},{"key":"10.1016\/j.jare.2020.01.008_b0625","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/cbdd.12102","article-title":"Discovery of thiazolidine-2,4-dione\/biphenylcarbonitrile hybrid as dual PPAR \u03b1\/\u03b3 modulator with antidiabetic effect: In vitro, in silico and in vivo approaches","volume":"81","author":"Hidalgo-Figueroa","year":"2013","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.jare.2020.01.008_b0630","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1016\/j.bmcl.2014.07.068","article-title":"Synthesis, in vitro and in silico studies of a PPAR\u03b3 and GLUT-4 modulator with hypoglycemic effect","volume":"24","author":"Navarrete-V\u00e1zquez","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jare.2020.01.008_b0635","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.biopha.2018.08.124","article-title":"Synthesis and evaluation of thiazolidine-2,4-dione\/benzazole derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B): Antihyperglycemic activity with molecular docking study","volume":"107","author":"Hidalgo-Figueroa","year":"2018","journal-title":"Biomed Pharmacother"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123220300084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123220300084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:48:46Z","timestamp":1761857326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2090123220300084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":127,"alternative-id":["S2090123220300084"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2020.01.008","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An overview on medicinal perspective of thiazolidine-2,4-dione: A remarkable scaffold in the treatment of type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2020.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}